抗病毒治疗热点难点_耐药和复发再治0606.pptVIP

* * ADV, adefovir; ETV, entecavir; HBeAg, hepatitis B e antigen; LAM, lamivudine; LdT, telbivudine. However, this next slide shows that prolonged treatment of more than 1 year with nucleos(t)ide analogues like lamivudine, adefovir, entecavir, or telbivudine can achieve increasing HBeAg seroconversion rates. Up to 50% of patients on lamivudine or adefovir for 5 years can achieve seroconversion. On a shorter time scale, 30% of patients on entecavir or telbivudine can achieve seroconversion within 2 years. For more information, go online to: /Hepatitis/Conference%20Coverage/Boston%202007/Tracks/H